Canaccord lowered the firm’s price target on Clover Health to $2 from $3 and keeps a Buy rating on the shares. The firm said management signaled the company will be placing greater emphasis on the MA business, continuing its balanced approach to growth and profitability, targeting high single to low double-digit growth in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLOV:
- Clover Health reports Q3 revenue $482.07M, consensus $494.6M
- Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance
- Clover Health options imply 11.6% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, November 06, 2023
- CLOV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
